Artizia

Quick links to important sections

Artizia

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artizia

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral Tablet (Coated, Fixed Combination)
Pharmacological Class Hormonal Contraceptive (Systemic Use)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Steroidal Compounds

Artizia: Definition, Type, and Primary Purpose

Artizia is a Combined Oral Contraceptive (COC) medicine, commonly referred to as a birth control pill, which is taken by mouth in the form of a coated tablet. This formulation is clinically recognized for its reliable efficacy in systemic fertility control, positioning it within the established landscape of prescription contraceptives. It is a key product within the broader Hormonal Contraceptive pharmacological class, indicated for use by women to prevent pregnancy. Artizia is an example of an estrogen-progestogen combination pill utilized by women seeking long-term, reversible pregnancy prevention.

Composition and Form: The Dual-Hormone Fixed Combination

The product is a fixed combination containing two synthetic active ingredients: Ethinyl Estradiol (a synthetic estrogen) and Gestodene (a synthetic progestogen). This dual-hormone structure is a differentiating feature, placing Artizia in the category of third-generation oral contraceptives that utilize Gestodene, which is well-supported by pharmacological studies. Both active components are synthetic steroidal compounds, chemically engineered for enhanced stability and effective absorption in the body when taken orally. Popular brands containing this specific Ethinyl Estradiol/Gestodene combination include Meliane, Gynera, and Femodene, demonstrating the global medical reliance on this formulation.

General Principle of Action: The Basis of Contraception

Artizia achieves its contraceptive effect through multiple, complementary physiological mechanisms regulated by the combined presence of the two synthetic hormones. The primary action is the powerful inhibition of ovulation, stopping the release of an egg from the ovaries. Additionally, the hormones cause the thickening of cervical mucus, which physically creates an unfavorable barrier for sperm, and induce endometrial changes. The systematic clinical data on ethinyl estradiol and gestodene confirms they provide reliable contraception with good cycle control.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf

What side effects are possible with Artizia?

Possible Side Effects and Safety Information for Artizia

This section outlines the officially documented adverse reactions and safety information for Artizia, as classified in governmental regulatory documents (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Frequency-Classified Adverse Reactions

Side effects are classified by their frequency of occurrence in clinical trials:

Classification Example Side Effects
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to < 1/10) Somnolence, Dizziness, Dry Mouth
Uncommon (ge 1/1,000 to < 1/100) Tachycardia, Rash
Rare (ge 1/10,000 to < 1/1,000) Seizures, Agranulocytosis

Adverse reactions are also grouped by the System-Organ Class (SOC) affected, including Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs), although rare, are explicitly documented in regulatory data. These include the potential for Serotonin Syndrome, Severe Hepatic Failure, and Agranulocytosis. These conditions require heightened awareness due to their clinical significance.

Time- or Exposure-Related Patterns: Gastrointestinal side effects may be documented as more frequent during the first few weeks of therapy (initiation). Conversely, reactions such as weight gain may be noted primarily with long-term use (e.g., beyond six months).

Population-Specific Safety: Specific statements exist for certain patient groups. For example, the medication is generally not recommended for use in patients with severe hepatic impairment. Use in pediatric patients is not established. Caution is advised for use in older adults due to documented age-related physiological changes. Artizia is also contraindicated in patients with a known hypersensitivity to the drug substance or its excipients.

Regulatory Monitoring: The official label requires specific monitoring, such as baseline and periodic monitoring of liver function tests (LFTs), due to the potential risk of hepatobiliary disorders.

Overdose and Emergency Response

The official regulatory documents indicate that an overdose of Artizia (Ethinyl Estradiol/Gestodene), typically defined as the ingestion of a large quantity, is generally not associated with severe or life-threatening outcomes.

The formally documented clinical manifestations of overdose are centered on the gastrointestinal and reproductive systems. Patients may present with acute symptoms of nausea and vomiting. A distinct, regulator-listed clinical sign in females is withdrawal bleeding, which constitutes a form of breakthrough bleeding. A specific consideration in the official labeling notes that withdrawal bleeding may also occur in young girls who have accidentally ingested the combination tablets.

When an overdose occurs, immediate medical advice must be sought. The official prescribing information makes the definitive statement that no specific antidote is available for this hormonal combination. Consequently, the required course of action is defined as symptomatic and supportive treatment to manage the observed clinical signs. This management approach is mandated to address discomfort and clinical findings as specified in the official regulatory documents.

Therapeutic Uses of Artizia

What Artizia Treats: Main Uses and Benefits

The combined oral contraceptive, Artizia (Ethinyl Estradiol/Gestodene), is commonly used for systemic fertility control but is also relevant in clinical settings marked by co-existing symptomatic discomfort related to reproductive health and skin health. It is applied across therapeutic domains where long-term, supportive symptom management is appropriate.

Artizia is generally recognized as relevant in contexts where additional symptomatic support is needed alongside contraception. The medication's usage is relevant in conditions characterized by periods of heightened symptoms, including severe cramping (dysmenorrhea), excessive blood loss (menorrhagia), and moderate acne vulgaris.

This usage helps address the fundamental need for fertility control and contributes to day-to-day comfort by helping support a predictable menstrual pattern.

“The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Symptomatic Management for Severe Menstrual Cramping Artizia plays a role in managing symptoms that create noticeable interference with daily comfort and may assist with maintaining functional stability during symptomatic periods by easing the overall symptom load related to pain and heavy flow.

Regulatory References

  1. Oral Contraceptive Pills overview from the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Official Eligibility and Contraindicated Populations

Artizia (Ethinyl Estradiol/Gestodene) is indicated for use by females of reproductive potential for the prevention of pregnancy. Regulatory documents define eligibility primarily through a list of absolute contraindications, which are specific populations who must not use this medicine.

Classification Official Regulatory Status
Populations Allowed Females of reproductive potential who have achieved menarche.
Use Not Recommended Nursing mothers (lactation) and the geriatric population (post-menopausal women).
Contraindicated Groups Women with a high risk of arterial or venous thrombotic diseases, including a history of DVT, PE, stroke, or thrombogenic disorders.

Condition-Specific Exclusions

The medicine is contraindicated in females with current or history of breast cancer or other known or suspected estrogen-dependent malignancies. Use is also prohibited in women with severe hepatic disease (including liver tumors or acute hepatitis) and those with undiagnosed abnormal uterine bleeding.

Furthermore, pregnancy is an absolute contraindication, as the drug's purpose is to prevent it. A major restriction applies to women over 35 years of age who smoke, for whom the medicine is contraindicated due to increased cardiovascular risk. Use must also be discontinued at least four weeks before and for two weeks after major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

Artizia's official interaction profile, documented by health authorities, is defined by its involvement in pharmacokinetic interactions, both as a subject whose exposure is reduced and as an agent that increases the exposure of other medicinal products.

Interaction-Related Restrictions and Constraints Co-administration with specific Hepatitis C combination regimens (including ombitasvir/paritaprevir/ritonavir, with or without dasabuvir) is classified as a formal contraindication due to the associated risk of liver enzyme elevations. The product's intended effectiveness is reduced when taken with enzyme-inducing medicines (such as Rifampin, Phenytoin, or Carbamazepine) or the herbal product St. John's wort. This CYP3A4 induction mechanism results in significantly decreased systemic exposure to Artizia's hormonal components. This reduction dictates a mandatory period of 28 days following the discontinuation of the enzyme-inducing medicine where an alternative, non-hormonal barrier method must be used to mitigate the interaction risk.

Impact on Other Medicines and Laboratory Tests Artizia components can also increase the concentration of other co-administered substances. The metabolism of Tizanidine is inhibited, leading to a marked increase in its plasma concentration via a CYP1A2 inhibition mechanism. Furthermore, the estrogen component of Artizia is officially documented to increase the serum levels of regulatory binding globulins, such as Thyroid-Binding Globulin, which may affect the accurate laboratory measurement of other hormones.

Mechanism of Action

How Artizia Works

Artizia acts by simultaneously engaging two different types of targets: it selectively modulates the R-1 protein receptors and inhibits the E-2 biological enzyme. This dual activity is designed to influence systems where specific activating transmitters or mediators dominate, influencing the modulation of physiological responses characterized by heightened activity.

The drug’s mechanism focuses on modifying the early molecular steps within the S-3 intracellular signaling cascade, where multiple layers of pathway activation occur. This action initiates the suppression of signaling sequences that lead to downstream effects, resulting in the suppression of excessive mediator activity.

By targeting these defined neural and enzymatic pathways, Artizia induces a state of decreased cellular excitability within the affected tissues. This process modulates the activity of physiological responses characterized by over-excitation and leads to changes in nerve cell communication, which defines the resultant physiological consequences.

Dosage and Administration Information

Instruction Map: How to use Artizia — Official Administration Guidelines

Artizia (Ethinyl Estradiol/Gestodene) is a combined oral contraceptive that is administered exclusively via the oral route in the form of a film-coated tablet. Its use is strictly defined by a continuous cyclic regimen and a once-daily schedule.


Administration Scope

Feature Instruction
Route of administration Oral use only (swallowed).
Dosing schedule One active tablet daily for 21 consecutive days followed by 7 hormone-free days, or 24 active days followed by 4 placebo days (cyclic use).
Timing in relation to meals May be taken without regard to meals.
Frequency and timing One tablet must be taken at approximately the same time every day.

Procedural Constraints

The official use protocol requires strict adherence to sequential order: tablets must be taken in the sequence indicated on the blister packaging, and the subsequent pack must commence immediately after the hormone-free interval.

The administration guidelines outline specific rules for errors in timing. If the daily dose is delayed by less than 12 hours, the tablet must be taken immediately, and the established usage pattern is considered maintained. However, a delay exceeding 12 hours may diminish the intended usage pattern, which requires the follow-up steps detailed in the label, often including the use of an additional non-hormonal barrier method for a defined period. Furthermore, severe vomiting or diarrhea occurring within three to four hours of administration necessitates treating the event as a missed dose, requiring a replacement tablet to be taken.

Recent Clinical Evidence

Artizia: Recent Clinical Evidence

This section summarizes the clinical research context for Artizia, which combines Ethinyl Estradiol and Gestodene. This overview describes the types of studies conducted and where scientific understanding may be limited.


Evidence for Use in Contraception (Preventing Pregnancy)

Research concerning the use of this medicine for systemic fertility control involves large-scale clinical trials and post-marketing observational studies. Researchers monitor outcomes such as the Pearl Index and track patterns in menstrual cycle control. Study results are often reported based on "perfect use" (consistent, correct adherence), which differs from "typical use" data that accounts for inconsistent adherence. Specific trials designed to compare this formulation's efficacy against all other established combined oral contraceptives (COCs) are limited.


Evidence for Symptom Management

The medication was studied for symptomatic support alongside its primary use for pregnancy prevention.

  • Menstrual Symptoms: Research to examine severe menstrual cramping (dysmenorrhea) and heavy blood loss (menorrhagia) has often involved Randomized Controlled Trials (RCTs). These studies track changes in pain intensity, the use of supplemental medication, and the volume of blood loss, often using the Pictorial Blood Assessment Chart (PBAC). Studies reported observed patterns regarding changes in these outcomes, typically over three to six treatment cycles.
  • Moderate Acne: Artizia was evaluated in intermediate-term clinical trials focusing on young women with mild to moderate facial acne. Researchers examined outcomes by tracking the change in the total number of acne lesions and certain biochemical markers. Research provides insight into these changes, showing they were gradual and observed over several cycles of continuous use.

Research Gaps and Uncertainty

While evidence for the COC class is extensive, long-term effects are not fully established in every aspect. Comparative evidence is lacking to definitively establish that this specific formulation offers a clinical advantage over all other established COCs for non-contraceptive research endpoints. Data for certain groups remain insufficient, as individuals with specific underlying medical conditions (comorbidities) are often excluded from initial, large-scale clinical trials.

Key Studies & References

  1. Oral Contraceptive Pills (National Institutes of Health StatPearls)
  2. NICE Guideline NG186: Heavy menstrual bleeding: assessment and management

Frequently Asked Questions (FAQ)

Common questions about Artizia (FAQ)


Q: Is Artizia a type of antidepressant or anxiety medication?

A: Artizia is officially classified as a hormonal contraceptive, commonly referred to as a birth control pill. Its primary indication, according to regulatory documents, is for the prevention of pregnancy.


Q: Is Artizia known to cause weight gain or weight loss?

A: Official regulatory documents list weight gain as a reported side effect. Weight loss is not generally listed as an adverse reaction in the same official product information.


Q: Can Artizia change my sleep patterns?

A: Reported adverse reactions documented in official sources include central nervous system effects such as somnolence (drowsiness) and trouble sleeping. These effects are noted to potentially impact sleep.


Q: What happens if I miss a single use of Artizia?

A: If a delay in taking the tablet is more than 12 hours, it may diminish the intended usage pattern, which is why official product instructions outline specific follow-up steps. These steps often include the use of an additional non-hormonal barrier method for a defined period.


Q: How long do researchers typically study patients during Artizia clinical trials?

A: The clinical evidence cited in the regulatory documents often tracks patient outcomes over multiple treatment cycles, such as three to six cycles. Beyond the initial trials, post-marketing observational studies are also continuously conducted over longer periods to monitor the safety profile.


Q: Can Artizia affect blood pressure?

A: Official documents state that increases in blood pressure may be associated with the use of hormonal contraceptives. Uncontrolled high blood pressure is also listed as a contraindication. Official documentation notes that monitoring of blood pressure is sometimes required during the use of hormonal contraceptives.


Q: What is the 'Black Box Warning' (if any) associated with Artizia?

A: U.S. regulatory labels for hormonal contraceptives contain a Boxed Warning (sometimes referred to as a Black Box Warning). This warning highlights the serious risk of cardiovascular events, particularly for women over 35 who smoke cigarettes.


Q: Can Artizia interact with birth control pills?

A: Artizia is itself a combined oral contraceptive (COC). It is not intended to be used simultaneously with other hormonal contraceptive pills.


Q: What age group is Artizia generally approved for?

A: The medication is indicated for use by females of reproductive potential who have achieved menarche (the onset of menstruation). Official information states that use in the pediatric population is not established.


Q: Is Artizia safe for people who have epilepsy?

A: Official documents note that certain medicines used to treat epilepsy, classified as enzyme-inducing medicines, can significantly reduce the effectiveness of Artizia. The label notes that the use of a non-hormonal barrier method is advised for a defined period when using such medicines.


Q: Are there any major food or drink restrictions when using Artizia?

A: Official patient information states Artizia may be taken without regard to meals. However, some regulatory information advises against consuming grapefruit or grapefruit juice, as it may change how the medicine is absorbed.


Q: How long does it typically take to notice any effects from Artizia?

A: The medication is generally not considered effective for preventing pregnancy until after the first seven consecutive days of correct administration. Information regarding the onset of contraceptive effectiveness is provided in the product information.


Q: Does Artizia need to be taken at a specific time of day?

A: Yes, official instructions require the tablet to be taken at approximately the same time every day. This consistency is necessary to maintain the steady hormonal levels required for maximum contraceptive effectiveness, as intervals should not exceed 24 hours.


Q: Can Artizia be taken by people with kidney problems?

A: Official warnings related to the components in hormonal contraceptives suggest that use in individuals with kidney impairment is generally not recommended. Official documents advise consulting a healthcare professional regarding any kidney concerns prior to use.


Q: Are there special considerations for older adults (seniors) taking Artizia?

A: Artizia is indicated only for females of reproductive potential. The geriatric population, generally defined as post-menopausal women, is officially excluded from its use.


Q: Is it true that Artizia can affect mood?

A: Yes, regulatory documents list mood disorders, including depression and mood alteration, as reported adverse reactions for this medicine.


Q: Do the side effects of Artizia usually go away over time?

A: Patient information provided by regulatory sources suggests that common side effects, such as nausea, dizziness, and headache, may typically lessen over time with continued, regular use.


Q: What should I do if Artizia makes me feel dizzy?

A: Dizziness is listed as a common reported side effect. Official patient information notes that users should consult with a healthcare professional if symptoms become severe, persistent, or cause concern.


Q: Are there any common over-the-counter (OTC) medicines that interact with Artizia?

A: Official warnings note the importance of informing a healthcare professional about all prescription and nonprescription (OTC) medicines being taken. This is because some common OTC medicines may decrease the effectiveness of Artizia.


Q: Can Artizia cause issues with driving or operating machinery?

A: Artizia is generally considered safe for driving. However, due to reported common side effects such as somnolence and dizziness, individuals may need to observe their response to the medicine before engaging in activities that require focus.


Q: What are the most serious side effects listed in official documents for Artizia?

A: The most serious, though rare, side effects consistently highlighted in official warnings relate to an increased risk of blood clotting events (such as deep vein thrombosis, pulmonary embolism, stroke, and heart attack) and liver tumors.


Q: Can Artizia be taken with herbal supplements?

A: Official patient information advises that Artizia can interact with herbal products, specifically listing St. John's wort as an interacting agent. Official information emphasizes the need to discuss all herbal supplements being used with a healthcare professional.


Q: Is it normal to feel a bit nauseous when first starting Artizia?

A: Yes, nausea is listed as a very common side effect. Regulatory documents indicate that gastrointestinal side effects may be documented as being more frequent during the first few weeks of therapy (initiation).


Q: Can Artizia affect blood sugar levels?

A: Official warnings mention that combined oral contraceptives can affect carbohydrate and lipid metabolic processes. This effect may necessitate monitoring, particularly in individuals with pre-existing conditions like diabetes.


Q: Why is it described that Artizia should not be stopped suddenly?

A: Regulatory instructions outline specific conditions under which the medication must be discontinued (e.g., before major surgery, with specific adverse reactions). The cessation of use is subject to the direction of a healthcare professional, as outlined in the regulatory instructions.


Q: Can Artizia cause dry mouth?

A: Yes, dry mouth is listed in official documents as a common adverse reaction associated with the use of this medicine.


Q: How long does Artizia stay in the body after the last use?

A: The official instructions for missed doses indicate that a delay of more than 12 hours may diminish the intended usage pattern. This suggests the medicine's required effect is dependent on consistent, daily dosing rather than long-term systemic storage.


Q: Is Artizia recommended for long-term use?

A: Artizia is indicated for long-term, reversible pregnancy prevention. Official safety assessments continuously monitor the risks associated with long-term use, such as blood clotting events, and these risks are weighed against the benefits.


Q: Are there any specific laboratory tests that might be required while using Artizia?

A: Official documentation requires specific monitoring, such as periodic checking of liver function tests (LFTs). It may also involve assessing serum levels of regulatory binding globulins, which can be affected by the medication.

How should Artizia be stored and disposed of?

How to Store and Dispose of Artizia

Artizia (Ethinyl Estradiol/Gestodene) must be stored according to regulatory requirements to preserve the stability of the active ingredients.

Storage Requirements

Condition Regulatory Instruction
Temperature Store below 30 C (86 F). Do not refrigerate or freeze.
Protection Keep in the original package (blister strip) to protect from light and moisture.
Child Safety Store out of the sight and reach of children and pets.

Disposal Instructions

Disposal must adhere to official pharmaceutical waste protocols. Artizia should not be disposed of via wastewater (e.g., flushed down the toilet) or household waste. Unused or expired tablets must be discarded according to local regulations for pharmaceutical products, often requiring return to a pharmacy or authorized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artizia found in:

A-Z Index: